Rights and permissions
About this article
Cite this article
Mitoxantrone plus prednisone justified in prostate cancer. Pharmacoecon. Outcomes News 175, 7 (1998). https://doi.org/10.1007/BF03277702
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03277702